Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Background & Aims Endoscopic ultrasound–guided choledochoduodenostomy with a lumen-
apposing metal stent (EUS-CDS) is a promising modality for management of malignant …

Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex most commonly
associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first described it in …

Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Simple Summary Pancreatic cancer remains a major therapeutic challenge despite medical
advances. The incidence of pancreatic cancer is increasing, and this disease is associated …

Importance Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and
gemcitabine plus nanoparticle albumin-bound (nab)–paclitaxel (GA) are first-line …

Pancreatic adenocarcinoma (PDAC) is predicted to become the second leading cause of
cancer deaths by 2030 and this is mostly due to therapy failure. Limited treatment options …

Background: Partial/complete pathologic response following neoadjuvant chemotherapy
(NAC) in pancreatic cancer (PDAC) patients undergoing pancreatectomy is associated with …